| Bioactivity | Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor[1]. | |||||||||
| Target | LSD1/MAO-B | |||||||||
| Invitro | Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2]. | |||||||||
| Name | Vafidemstat | |||||||||
| CAS | 1357362-02-7 | |||||||||
| Formula | C19H20N4O2 | |||||||||
| Molar Mass | 336.39 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018. |